Goldman Sachs Maintains Sell on PTC Therapeutics, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Paul Choi maintains a 'Sell' rating on PTC Therapeutics (NASDAQ:PTCT) and has lowered the price target from $35 to $22.
September 18, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs has maintained a 'Sell' rating on PTC Therapeutics and lowered the price target from $35 to $22.
The 'Sell' rating maintained by Goldman Sachs indicates a negative outlook for PTC Therapeutics. The lowering of the price target from $35 to $22 suggests that the analyst believes the stock is overvalued at its current price, which could lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100